Pharma BD Deal Intelligence

Eli Lilly and Company / CoLucid Pharmaceuticals

2017 · Acquisition/Merger · $960M · Complete

Announcement Sentiment

88

Strongly positive

Outcome Score

57

Mixed — partial payoff, real shortfalls.

Lilly acquired CoLucid for $960M for migraine therapy lasmiditan.

Key facts

Announced Jan 18, 2017
Closed Mar 01, 2017
Deal value $960M
Deal type Acquisition/Merger
Therapeutic area Neurology
Key assets lasmiditan

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals